Axsome Therapeutics
AXSM
169 hedge funds and large institutions have $2.31B invested in Axsome Therapeutics in 2019 Q4 according to their latest regulatory filings, with 69 funds opening new positions, 41 increasing their positions, 50 reducing their positions, and 11 closing their positions.
527% more first-time investments, than exits
New positions opened: 69 | Existing positions closed: 11
496% more capital invested
Capital invested by funds: $387M → $2.31B (+$1.92B)
140% more funds holding in top 10
Funds holding in top 10: 5 → 12 (+7)
99% more call options, than puts
Call options by funds: $251M | Put options by funds: $126M
52% more funds holding
Funds holding: 111 → 169 (+58)
5.82% more ownership
Funds ownership: 54.97% → 60.79% (+5.8%)
18% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 50
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$36.3M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$24.2M |
| 3 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$22.9M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$18.3M |
| 5 |
HM
HealthCor Management
New York
|
+$16.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$20.1M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$19.2M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$13.6M |
| 4 |
ACM
Alethea Capital Management
Mercer Island,
Washington
|
-$12.2M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$12M |
AXSM Hedge Fund Activity: Q4 2019 in Review
169 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q4 2019, worth a combined $2.31B — up 496% from $387M a quarter earlier.
Buyers outnumbered sellers: 69 funds opened new AXSM positions and 11 closed out — a net gain of 58 holders — while 41 added to existing stakes and 50 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $36.3M. The largest seller was AllianceBernstein, cutting an estimated $20.1M.
- 169 institutional investors held Axsome Therapeutics (AXSM) as of Q4 2019, up from 111 in Q3 2019.
- Funds reported $2.31B of Axsome Therapeutics stock for Q4 2019, up 496% quarter-over-quarter.
- 69 funds opened new Axsome Therapeutics positions in Q4 2019 and 11 closed out, a net change of +58 holders.
- The largest Axsome Therapeutics buyer in Q4 2019 was T. Rowe Price Associates, an estimated $36.3M added.
- The largest Axsome Therapeutics seller in Q4 2019 was AllianceBernstein, an estimated $20.1M sold.
Based on aggregated 13F filings for Q4 2019.